Document Detail


Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.
MedLine Citation:
PMID:  23352204     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Strategies that block angiotensin II actions on its angiotensin type 1 receptor or inhibit actions of aldosterone have been shown to reduce myocardial hypertrophy and interstitial fibrosis in states of insulin resistance. Thereby, we sought to determine if combination of direct renin inhibition with angiotensin type 1 receptor blockade in vivo, through greater reductions in systolic blood pressure (SBP) and aldosterone would attenuate left ventricular hypertrophy and interstitial fibrosis to a greater extent than either intervention alone.
MATERIALS/METHODS: We utilized the transgenic Ren2 rat which manifests increased tissue expression of murine renin which, in turn, results in increased renin-angiotensin system activity, aldosterone secretion and insulin resistance. Ren2 rats were treated with aliskiren, valsartan, the combination (aliskiren+valsartan), or vehicle for 21 days.
RESULTS: Compared to Sprague-Dawley controls, Ren2 rats displayed increased systolic blood pressure, elevated serum aldosterone levels, cardiac tissue hypertrophy, interstitial fibrosis and ultrastructural remodeling. These biochemical and functional alterations were accompanied by increases in the NADPH oxidase subunit Nox2 and 3-nitrotyrosine content along with increases in mammalian target of rapamycin and reductions in protein kinase B phosphorylation. Combination therapy contributed to greater reductions in systolic blood pressure and serum aldosterone but did not result in greater improvement in metabolic signaling or markers of oxidative stress, fibrosis or hypertrophy beyond either intervention alone.
CONCLUSIONS: Thereby, our data suggest that the greater impact of combination therapy on reductions in aldosterone does not translate into greater reductions in myocardial fibrosis or hypertrophy in this transgenic model of tissue renin overexpression.
Authors:
Adam Whaley-Connell; Javad Habibi; Nathan Rehmer; Sivakumar Ardhanari; Melvin R Hayden; Lakshmi Pulakat; Caroline Krueger; Carlos M Ferrario; Vincent G DeMarco; James R Sowers
Related Documents :
7116704 - Pressor effects of indomethacin in two anephric patients with chronic hypotension.
19965794 - The relationship of right- and left-sided filling pressures in patients with heart fail...
21402344 - Blood pressure and working conditions in hospital nurses and nursing assistants. the or...
18614724 - Acute dark chocolate and cocoa ingestion and endothelial function: a randomized control...
10372974 - Sustained vessel dilation induced by increased pulsatile perfusion of porcine carotid a...
23137044 - Do lower cuff pressures reduce damage to the tracheal mucosa? a scanning electron micro...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2013-01-24
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  62     ISSN:  1532-8600     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-05-21     Completed Date:  2013-07-17     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  United States    
Other Details:
Languages:  eng     Pagination:  861-72     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aldosterone / blood
Amides / pharmacology
Angiotensin II Type 1 Receptor Blockers / pharmacology*
Animals
Blood Pressure
Cell Size
Drug Interactions
Fibrosis
Fumarates / pharmacology
Mice
Myocardium / pathology*,  ultrastructure
Myocytes, Cardiac / drug effects,  pathology
Oxidative Stress*
Rats
Rats, Sprague-Dawley
Rats, Transgenic
Receptor, Angiotensin, Type 1 / metabolism*
Renin / antagonists & inhibitors*,  genetics
Signal Transduction
Tetrazoles / pharmacology
Valine / analogs & derivatives,  pharmacology
Ventricular Remodeling
Grant Support
ID/Acronym/Agency:
AG040638/AG/NIA NIH HHS; HL-051952/HL/NHLBI NIH HHS; HL-107910/HL/NHLBI NIH HHS; HL-73101/HL/NHLBI NIH HHS; R01 HL073101/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Amides; 0/Angiotensin II Type 1 Receptor Blockers; 0/Fumarates; 0/Receptor, Angiotensin, Type 1; 0/Ren2 protein, mouse; 0/Ren2 protein, rat; 0/Tetrazoles; 137862-53-4/valsartan; 4964P6T9RB/Aldosterone; 502FWN4Q32/aliskiren; EC 3.4.23.15/Renin; HG18B9YRS7/Valine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Large-scale brain networks in affective and social neuroscience: towards an integrative functional a...
Next Document:  Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcom...